Skeletal-targeted radiation to treat bone-associated pathologies
The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
1. A therapeutic pharmaceutical dosage form comprising:
(a) an amount of 153 Sm-EDTMP effective for suppressing the bone marrow of a human;
(b) an effective antiradiolytic amount of a pharmaceutically acceptable radioprotectant; and
(c) an aqueous vehicle.
2. The dosage form of claim 1 wherein the amount of 153 Sm-EDTMP is effective to deliver a dose of at least about 15 Gy of radiation to the bone marrow of a human patient.
3. The dosage form of claim 1 wherein the amount of 153 Sm-EDTMP is effective to deliver a dose of about 30-40 Gy of radiation to the bone marrow of a human patient.
4. The dosage form of claim 1 wherein the amount of EDTMP is effective to deliver a dose of about 20-30 Gy of radiation to the bone marrow of a human patient.
5. The dosage form of claim 1 wherein the amount of 153 Sm-EDTMP is effective to deliver a dose of about 250-3000 MBq/kg to a human patient.
6. The dosage form of claim 1 wherein the amount of 153 Sm-EDTMP is effective to ablate the bone marrow of a human.
7. The dosage form of claim 1 wherein the radioprotectant is an ascorbate or gentisic acid.
8. The dosage form of claim 7 wherein the ascorbate is ascorbic acid at a concentration of about 35-75 mg/ml.
9. The dosage form of claim 1 wherein the vehicle is buffered to about pH 7-8.